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Background:  As  an  evolution  of  its currently  licensed  rabies  vaccine  Verorab®, Sanoﬁ  Pasteur  has  devel-
oped a next-generation,  serum-free,  highly  puriﬁed  Vero  rabies  vaccine  (PVRV-NG).  Through  this  Phase  III
clinical  trial,  we  aimed  to demonstrate  the  non-inferiority  of  PVRV-NG  over  Verorab  when  administered
according  to  a post-exposure  regimen  and  to  assess  its clinical  safety.
Methods:  A  total  of 816  healthy  subjects  aged  ≥10  years  were  randomized  according  to  a 2:1 ratio  to
receive  PVRV-NG  or  Verorab.  Half  of the  subjects  were  aged  10–17  years,  the  other  half  were  aged  ≥18
years.  All  subjects  were  to  receive  5  injections  on  days  0,  3,  7, 14  and  28.  Three  blood  samples  were  taken
for rabies  virus  neutralizing  antibodies  (RVNA)  assessment,  at  baseline,  on day  14  and  day  42.  Solicited
adverse  reactions  (between  injections  1, 2  and  3, and  within  7  days  post-injections  4  and  5)  and  adverse
events (up  to 28  days  after  the  last  injection)  were  collected  for  clinical  safety  assessment;  serious  adverse
events  were  reported  up to  6-months  after  the  last  injection.
Results:  The  proportion  of  subjects  with  an RVNA  titer  ≥0.5  IU/mL  after  the  third  injection  of PVRV-NG  was
non-inferior  to the  proportion  of  those  who  received  Verorab.  PVRV-NG  was  shown  to be as  immunogenic
as Verorab  in  each  age  range  in  the  per-protocol  and  full analysis  sets.  PVRV-NG  induced  a strong  immune
response  in both  age  ranges,  with  high  RVNA  levels  and  increased  geometric  mean  titers  compared  to
baseline  after  each  measured  time  point.  PVRV-NG  had  a  satisfactory  safety  proﬁle  after  each  injection,
similar to Verorab  with  regards  to  the  nature,  frequency,  duration  and  severity  of  adverse  events.  Two
serious  adverse  events  were  reported,  none  was  related  to  vaccination.
Conclusions:  This  trial demonstrated  the  immunogenic  non-inferiority  of  PVRV-NG  over Verorab  and
nes  have  similar  safety  proﬁles.  This  trial  is  registered  at  ClinicalTrials.gov
nuscript  is  the  ﬁrst  full  report  of  the  study.  An  abstract  of  the  study  results
 at the  Rabies  in  the  Americas  (RITA)  conference  in  October  2012  in  São  Paulo,showed  that  both  vacci
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1. Introduction
Rabies has been known for over 4000 years, yet the disease is
still largely present worldwide with 150 countries and territories
still affected. This viral, zoonotic disease remains a public health
concern in developing countries and still kills an estimated 61,000
people every year in the world, especially in Asia and Africa [1].
Open access under CC BY license. People may  become infected after exposure with infected animal
saliva, through bites, licks and scratches, and rabies is almost always
fatal if left untreated. If wild rabies vector species, such as raccoons,
foxes, skunks, and bats, represent a high risk to the populations,
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omestic animals may  also carry and transmit the disease. Rabies
n dogs accounts for the main cause of rabies-induced morbidity
nd mortality in humans and puts over 3.3 billion people at risk of
eing exposed to the disease [2].
There is no known treatment against rabies; human rabies
revention relies largely on vaccination. Cell-based rabies vac-
ines have a well-established safety and efﬁcacy proﬁle from their
dministration to millions of people worldwide over more than
orty years. These vaccines may  be used for both pre-exposure
rophylaxis (PrEP) and post-exposure prophylaxis (PEP). PrEP is
ecommended for anyone who will be at continual, frequent, or
ncreased risk of rabies exposure. PEP is recommended depending
n the type of exposure and the vaccination status of the patient.
ach year, over 15 million people worldwide receive PEP regi-
en, which prevents an estimated 327,000 annual deaths from
abies [2]. The World Health Organization (WHO) has deﬁned
hree categories of contact from the least (Category I) to the
ost serious (Category III); depending on the category, PEP may
nclude vaccination in conjunction with local wound cleansing
nd the simultaneous administration of rabies immunoglobulins
RIG) [1,3]. Several WHO-approved rabies vaccination schedules
ave shown to be immunogenic for PEP via the intramuscular (IM)
oute, such as the 5-dose Essen regimen and the 4-dose Zagreb
egimen, or via the intradermal (ID) route, such as the Thai Red
ross (TRC) 2-site regimen [1,3]. Rabies vaccines are expected to
eet the WHO  recommended potency of ≥2.5 IU per single IM dose
nd to induce an antibody (Ab) response at a minimum titer of
.5 IU/mL of serum, as measured by the rapid ﬂuorescent focus inhi-
ition test (RFFIT) or the ﬂuorescent antibody virus neutralizing test
FAVN).
Two rabies vaccines are currently manufactured by Sanoﬁ
asteur: a human diploid cell vaccine (HDCV), Imovax® Rabies,
nd a puriﬁed Vero cell rabies vaccine (PVRV), Verorab®. In an
ffort toward continuous improvement of its vaccine production
rocess, Sanoﬁ Pasteur has developed an improved serum-free,
uriﬁed Vero cell rabies vaccine (PVRV Next Generation [PVRV-
G]) which will replace both Verorab® and Imovax® Rabies. This
ext-generation vaccine is prepared from the inactivated Pitman-
oore strain common to Verorab and Imovax Rabies. It is produced
ith the same potency of ≥2.5 IU/dose but without any com-
onent of human or animal origin and without antibiotics. The
esulting virus is highly puriﬁed prior to its inactivation by beta
ropiolactone and thoroughly characterized, thus improving its
verall robustness. In addition, as is widely acknowledged, the
bsence of components of animal or human origin eliminates the
isk of contamination with non-conventional transmissible agents
uch as those associated with Bovine Spongiform Encephalopathy
BSE) and scrapie. PVRV-NG has a very low residual DNA content
100 pg/dose) while keeping the same key attributes as Verorab, as
emonstrated by the pharmaceutical comparability study using the
CH Q5E standards [4]. The comparability of Verorab and PVRV-NG,
ith regards to safety and immunogenicity, was demonstrated in
 recent Phase II clinical trial [5]. Further to this, and as PVRV-NG is
n evolution of Verorab, the extensive clinical data and ﬁeld expe-
ience with Verorab are considered to be supportive of the safety,
mmunogenicity and efﬁcacy of PVRV-NG.
In China, where the present study was conducted, rabies
emains a public health issue. The country reports the second high-
st number of human cases after India, with more than 117,500
eaths and three major epidemics since 1950. Over the last 15 years,
ore than 25,000 people have died of rabies in China in a context
f high population density and low dog vaccination coverage [6].
abies vaccination in China is used mainly for PEP according to the
-dose Essen regimen. This study aimed to generate data in humans
n the immunogenicity and safety of PVRV-NG when administered
n a post-exposure regimen and to show that PVRV-NG is at least as013) 5940– 5947 5941
immunogenic as Verorab with regards to seroconversion rate after
three injections.
2. Methods
This was a phase III, blind-observer, controlled, randomized,
monocenter trial in China.
2.1. Participants
The 816 participants aged ≥10 years were randomized accord-
ing to a 2:1 ratio to receive PVRV-NG (Group 1: 544 participants)
or Verorab (Group 2: 272 participants). Half of the subjects were
aged 10–17 years, the other half were ≥18 years. In each age range,
there were 272 subjects in Group 1 and 136 in Group 2. Subjects
were not included in the trial if they had been previously vac-
cinated against rabies for pre- or post-exposure; if they planned
to receive other vaccinations during the trial period; if they had
known or suspected congenital or acquired immunodeﬁciency or
known systemic hypersensitivity to any of the vaccine compo-
nents; if they had a chronic illness; if they were at high risk of
rabies exposure during the trial or had current alcohol abuse or
drug addiction. Pregnant women, or women likely to be pregnant,
were not included. Subjects who were HIV or hepatitis C positive or
who  had received blood or blood-derived products in the 3 months
prior to enrolment were excluded.
2.2. Ethics
The trial complied with the Declaration of Helsinki, ICH guide-
lines for good clinical practice (GCP) and all applicable local and
national regulations and directives. We  obtained written assent
from all subjects aged 10–11 years and written informed consent
from all subjects aged ≥12 years. The parents or legal guardians of
subjects <18 years also provided written consent.
2.3. Interventions
Both study vaccines are freeze-dried puriﬁed inactivated rabies
vaccines prepared on Vero cells and manufactured by Sanoﬁ Pas-
teur. Each dose of vaccine contained ≥2.5 IU inactivated rabies
virus (Wistar Rabies Pitman Moore/WI 38 1503-3M strain) to be
diluted in 0.5 mL  sodium chloride before use. Two needles were
supplied (16 and 25 mm),  one for product reconstitution and one
for IM administration, at the vaccinator’s discretion. PVRV-NG and
Verorab were released under batch numbers S4256 and E0589-1,
respectively.
Participants received ﬁve deltoid injections on Days (D)  0, 3,
7, 14 and 28. The study was conducted in simulated post-exposure
condition without administration of RIG. Blood samples were taken
on D0 (before the ﬁrst dose), D14 (before the fourth dose) and D42
(14 days after the last dose).
2.4. Objectives and outcomes
The primary objective was  to demonstrate that PVRV-NG is at
least as immunogenic as Verorab. The primary endpoint was the
seroconversion status at D14 (rabies virus neutralizing antibody
[RVNA] titer ≥0.5 International Unit [IU]/mL) measured by a RFFIT.
The secondary objectives were to assess the safety of PVRV-NG after
each injection, in each age range and overall, and to describe the
immune response induced by PVRV-NG after 3 injections and 14
days after the last injection, in each age range and overall. Clini-
cal safety was assessed based on the occurrence of solicited (pain,
erythema, and swelling) and unsolicited injection site reactions in
the 7 days after each injection; solicited systemic reactions (fever,
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eadache, malaise, and myalgia) between the ﬁrst and the sec-
nd injections, between the second and the third injections, and
hen within 7 days after each subsequent injection; unsolicited sys-
emic adverse events (AEs) between injections and 28 days after
he last injection; serious adverse events (SAEs) throughout the
rial until 6 months after the last injection. Adverse events and
eactions were measured as per the “Guideline for Rating Scales of
dverse Reaction of Clinical Trials of Preventive Vaccines” released
y the Chinese FDA in October 2005. Unsolicited AEs and SAEs were
eferred to as adverse reactions (ARs) or serious adverse reactions
SARs) if the investigators considered that they were related to
accination.
.5. Sample size
In each age range, it was  estimated that 230 participants in the
VRV-NG group and 115 in the Verorab group were necessary, using
he Farrington and Manning method, with an alpha level of 2.5%
one-sided hypothesis), a minimum clinically relevant difference
f 5% for the seroconversion rate at D14, a power of at least 95%, an
ssumed seroconversion rate of 99% for both vaccines, and 2:1 ran-
omization. Assuming that 15% would not be evaluable, each age
ange had to include 272 (Group 1) and 136 (Group 2) participants
or a total of 544 and 272 participants in each group, respectively.
.6. Randomization and blinding
Participants were randomized via a scratchable randomization
ist created using the permuted block method with stratiﬁcation by
ge range. The list mentioned the inclusion number of the partici-
ant and the corresponding vaccine to be administered.
The trial used an observer-blind design so that both vaccines
ere prepared in the absence of the subject and administered by
omeone not in charge of safety assessment. The subject was  not
ware which vaccine was injected.
.7. Statistical methods
The immunogenicity of PVRV-NG was compared to that of
erorab using a non-inferiority test in each age range. The pri-
ary parameter was the proportion of subjects with an RVNA
iter ≥0.5 IU/mL after the third dose. The two-sided 95% conﬁdence
nterval (CI) of the difference in the proportion of subjects with an
VNA titer ≥0.5 IU/mL was used. The non-inferiority of PVRV-NG
as demonstrated in each age range if the lower bound of the 95%
I of the difference between PVRV-NG and Verorab was  >−5%.
Three analysis sets were deﬁned:
The Per-Protocol Analysis Set (PPAS) excluded participants who
ere seropositive on D0 (i.e. >lower limit of quantitation [LLOQ]),
ho did not provide a blood sample, who did not have a valid test
esult available at both D0 and D14, who had not been vaccinated
ccording to the protocol or did not fully comply with the protocol.
The Full Analysis Set (FAS) was deﬁned for the descriptive analy-
is of immunogenicity. All randomized subjects who  had received
he ﬁrst dose were included.
The Safety Analysis Set (SafAS) was deﬁned for each dose as the
ubset of subjects who received this dose. Participants were ana-
yzed according to the vaccine received at this dose. For the analysis
t any dose, participants were analyzed according to the vaccine
eceived at the ﬁrst dose..8. Laboratory methods
Serum samples were assayed for RVNA determination at the
ational Institutes for Food and Drug Control (NIFDC, Beijing,2013) 5940– 5947
China) using an RFFIT. The method is described in the Chinese
Pharmacopeia [7].
3. Results
3.1. Participant ﬂow
A total of 816 subjects were enrolled in the study between April
and August 2011, 544 were randomized to Group 1 (PVRV-NG) and
272 to Group 2 (Verorab). Each group included subjects aged 10–17
years or ≥18 years; in each age range, there were 272 subjects in
Group 1 and 136 in Group 2 (Figs. 1 and 2).
The most frequent reason for discontinuation was voluntary
withdrawal not due to an AE. Respectively in each group, 508 and
256 subjects received the full 5-dose schedule, and 507 and 255
were still present 28 days after Dose 5. Out of 66 subjects with
protocol deviations (45 in Group 1 and 21 in Group 2) leading to
exclusion from the per-protocol analysis, 49 were excluded because
their post-dose 3 serology sample was not performed as a result, in
most cases, of not receiving the required ﬁrst three injections.
3.2. Baseline data
The study population had comparable baseline characteristics
between Group 1 and Group 2 (Table 1): in each age range, the mean
age of the subjects was  similar between the groups, an unbalanced
sex ratio in favor of female subjects was observed in each group
(and was more marked in Group 2), and all subjects were of Asian
origin. Baseline characteristics and demographic data were similar
in the FAS and PPAS (Table 2).
3.3. Immunogenicity
As presented in Table 3, in each age range, all subjects included
in the PPAS were naïve to rabies at baseline (RVNA titer ≤ LLOQ of
0.14 IU/mL before vaccination). After the third injection, the sero-
conversion threshold was  reached in all subjects in the younger
age range and in all but 2 subjects, 1 from each group, in the older
age range. The lower bound of the conﬁdence interval of the differ-
ence between PVRV-NG and Verorab was >−5.0% in each age range,
thus demonstrating the non-inferiority of PVRV-NG over Verorab.
Similar results were observed in the FAS which included all ran-
domized subjects who received the ﬁrst vaccination, regardless of
their baseline RVNA status.
The study also aimed to describe the immune response induced
by PVRV-NG after 3 doses, and 14 days after the last injection in
each age range and overall.
In the younger age range (10–17 years), ﬁve subjects in each
group had detectable RVNA titers before the ﬁrst dose but none
had a titer ≥ the WHO  seroconversion threshold of 0.5 IU/mL. Pre-
vaccination Geometric Mean Titers (GMTs) were close to 0.07 IU/mL
in both groups. All subjects reached protective levels of RVNA titers
after the third dose with an increase in GMTs to 7.26 (6.50; 8.11)
IU/mL in Group 1 and 8.81 (7.60; 10.2) IU/mL in Group 2 and a
further increase 14 days after the last dose to 9.61 (8.60; 10.7) IU/mL
in Group 1 and 11.8 (10.2; 13.5) IU/mL in Group 2.
In the older age range (≥18 years), three subjects in each group
had detectable RVNA titers before the ﬁrst dose but none had a titer
as high as 0.5 IU/mL. All subjects reached protective levels of RVNA
titers after the third dose, except for two  women  aged 59 years
who  reached the 0.5 IU/mL threshold after the ﬁfth dose of PVRV-
NG (2.70 IU/mL) and Verorab (0.86 IU/mL). As was observed in the
younger age range, GMTs were close to 0.07 IU/mL in both groups
before vaccination, increased after the third dose (2.75 [2.40; 3.16]
IU/mL in Group 1 and 3.76 [3.12; 4.55] IU/mL in Group 2), and
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N Planned = 408 
N randomized = 408 
PVRV -NG 
N Planned = 272 
N randomized = 272 
N at V01 = 272 
N blood sample = 272 
N vaccinated = 272 
N at V02 = 256* 
N vaccinat ed = 255 
N at V03 = 251 
N vaccinat ed = 251 
N at V04 = 250 
N blood sample = 250 
N vaccinat ed = 250 
N at V05 = 249 
N vaccinat ed = 249 
N at V06 = 249 
N blood sample = 249 
N at V07 = 249 
N 6-month follow-up = 253 
N discontinued = 17 
14 volunt ary withdr ew and  
3 had an AE. 
N discontinued =  4 
3 volu ntary withdrew  and  
1 had an AE. 
N discontinued =  1 
1 voluntary withdrawal 
N discontinued =  1 
1 voluntary withdrawal 
Ver orab 
N Planned = 136 
N randomized = 136 
N at V01 = 136 
N blood sample = 136 
N vaccinated = 136 
N at V0 2 = 130* 
N vaccinated = 12 9 
N at  V03 = 129 
N vaccinated = 12 9 
N at  V04 = 129 
N blood sample = 129 
N vaccinated = 12 9 
N at  V05 = 127 
N vaccinated = 12 7 
N at  V06 = 127 
N blood sample = 127 
N at  V07 = 127 
N 6-month follow-up = 129 
N discontinued =  7 
5 volu ntary withdrew  and  
2 had an AE. 
N discontinued =  2 
2 voluntary withdrawal 
Fig. 1. Flow diagram – Participants aged 10–17 years – Full Analysis Set.
*1  participant present at V02 but not vaccinated and therefore discontinued.
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N Planned = 408
N ran domize d = 40 8 
PVRV-NG 
N Planned = 272  
N randomized = 272 
N 6-month follow-up = 262 
N discon tinu ed = 6 
4 voluntary withdrew and  
2 had  an  AE. 
N discon tinu ed = 5 
3 voluntary withdrew and  
1 had  an  AE and 1 an  SAE. 
N discon tinu ed = 2 
voluntary withdrawal 
Verorab 
N Planned = 13 6 
N randomized = 136 
N 6-month follow-up  = 128 
N discontinued = 6
volun tary withdrawal 
N discontinu ed = 1
voluntary withdrawal 
N discontinued  = 1 
voluntary withdrawal 
N discontinued = 1
volun tary withdrawal 
N at V02 = 266 
N vaccinated = 266 
N at V01 = 272 
N blood sample = 272 
N vaccinated = 272 
N at V04 = 259 
N blood sample = 259  
N vaccinated = 259 
N at V05 = 259 
N vaccinated = 259 
N at V06 = 258 
N blood sample = 258  
N at V07 = 258 
N at V03 = 262*  
N vaccinated = 261 
N at V01 = 136
N blood sample = 136 
N vac cinated = 136 
N at V02 = 130
N vac cinated = 130 
N at V03 = 129 
N vac cinated = 129 
N at V04 = 129
N blood  sample = 129 
N vac cinated = 129 
N at V05 = 129
N vac cinated = 129 
N at V06 = 128
N blood  sample = 128 
N at V07 = 128 
Fig. 2. Flow diagram – Participants aged ≥18 years – Full Analysis Set.
2  participants who were randomized to receive PVRV-NG received Verorab by mistake at D0.
*The subject with the SAE attended V03 but was  not vaccinated as she was discontinued from the study at that visit.
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Table  1
Baseline characteristics and demography according to randomized vaccine group – Full Analysis Set.
10–17 years 18 years and over
PVRV-NG (N = 272) Verorab (N = 136) PVRV-NG (N = 272) Verorab (N = 136)
Age at D0 (years)
M (available data) 272 136 272 136
Mean  (SD) 12.8 (1.9) 12.5 (1.8) 43.5 (10.6) 44.0 (9.6)
Minimum; Maximum 10.0; 17.4 10.0; 17.7 18.1; 60.5 20.4; 59.7
Gender
Male:  n (%) 121 (44.5) 51 (37.5) 95 (34.9) 52 (38.2)
Female: n (%) 151 (55.5) 85 (62.5) 177 (65.1) 84 (61.8)
Male/female ratio 0.80 0.60 0.54 0.62
Ethnic  origin: n (%)
Asian 272 (100.0) 136 (100.0) 272 (100.0) 136 (100.0)
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Subject disposition in each analysis set.
PVRV-NG Verorab Total
N Full Analysis Set 544 272 816
10–17 years (n) 272 136 408
≥18  years (n) 272 136 408
N  Per-Protocol Analysis Set 499 251 750
10–17 years (n) 245 126 371
≥18  years (n) 254 125 379
N  Safety Analysis Seta
Dose 1 542 274 816
10–17 years (n) 272 136 408
≥18  years (n) 270 138 408
Dose 2 521 259 780
10–17 years (n) 255 129 384
≥18  years (n) 266 130 396
Dose 3 511 259 770
10–17 years (n) 251 129 380
≥18  years (n) 260 130 390
Dose 4 508 259 767
10–17 years (n) 250 129 379
≥18  years (n) 258 130 388
Dose 5 507 257 764
10–17 years (n) 249 127 376
≥18  years (n) 258 130 388
T
N
a
n
M18 Years and above10 to 17 years
ig. 3. RVNA Geometric Mean Titers (GMTs) – RFFIT method – Full Analysis Set.
urther increased after the ﬁfth dose (5.09 [4.52; 5.74] IU/mL in
roup 1 and 5.72 [4.86; 6.73] IU/mL in Group 2). See Fig. 3.
In all subjects overall and in each age range separately, GMTs
ended to be slightly higher with Verorab than with PVRV-NG after
he third and after the ﬁfth injections. This was considered to be
f limited clinical signiﬁcance since RVNA titers reached levels far
bove 0.5 IU/mL in both groups.
Based on the homogeneity test performed after the third injec-
ion, gender and age were shown to have no impact on the response
o vaccination.
.4. Safety
An overview of safety data after any injection is presented in
able 4.
There were no related SAEs during the trial. Two unrelated
AEs were reported (two adult subjects randomized to Group 1
eported dog bites). No immediate (i.e. occurring within 30 min
ost-vaccination) unsolicited AEs were reported in any of the
roups. Group 1 and Group 2 reported similar proportions of
olicited reactions, unsolicited AEs and unsolicited ARs.
able 3
on-inferiority of PVRV-NG versus Verorab – Proportions of subjects with RVNA titer ≥0
PVRV-NG (N = 499) Veror
n/M % (95% CI) n/M 
10–17 years
Subjects with RVNA titer
≥0.5 IU/mL at D0
0/245 0.0 (0; 1.49) 0/126
Subjects with RVNA titer
≥0.5 IU/mL at D14
245/245 100.0 (98.5; 100) 126/1
18  years and over
Subjects with RVNA titer
≥0.5 IU/mL at D0
0/254 0.0 (0; 1.44) 0/125
Subjects with RVNA titer
≥0.5 IU/mL at D14
253/254 99.6 (97.8; 100) 124/1
Non-inferiority concluded if the low limit of the two-sided 95% CI of the difference PVR
:  number of subjects experiencing the endpoint.
:  number of subjects with available data for the relevant endpoint.a Based on the vaccine received at each dose.
Solicited reactions tended to be more frequently systemic than
injection site reactions and they occurred in higher proportions in
the younger age range (see Figs. 4 and 5). Unsolicited AEs occurred
in low proportions in Group 1 and Group 2, none of them was
reported at the site of injection and the majority was assessed
as not related. In younger subjects, unsolicited AEs were mostly
Grade 1 or Grade 2 in severity, occurred within 3 days and resolved
in a maximum of 14 days. In older subjects, unsolicited AEs were
mostly Grade 1 in severity, occurred within 3 days and resolved in a
.5 IU/mL at D14 by group – RFFIT method – Per-Protocol Analysis Set.
ab (N = 251) PVRV-NG Verorab Non-inferioritya
% (95% CI) % (95% CI) Yes/No
 0.0 (0; 2.89) 0.0 (−2.96; 1.54) Yes
26 100.0 (97.1; 100) 0.0 (−1.54; 2.96)
 0.0 (0; 2.91) 0.0 (−2.98; 1.49) Yes
25 99.2 (95.6; 100) 0.4 (−1.51; 4.01)
V-NG – Verorab for proportion of subjects with RVNA titer ≥0.5 IU/mL is >−5.0%.
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Table 4
Safety overview during the trial – Safety Analysis Set – All subjects.
PVRV-NG (N = 542) Verorab (N = 274)
Subjects experiencing at least one: n/M % (95% CI) n/M % (95% CI)
Immediate unsolicited AE 0/542 0.0 (0.0; 0.7) 0/274 0.0 (0.0; 1.3)
Solicited reaction 116/540 21.5 (18.1; 25.2) 63/274 23.0 (18.1; 28.4)
Solicited injection site reaction 60/540 11.1 (8.6; 14.1) 34/274 12.4 (8.7; 16.9)
Solicited systemic reaction 86/540 15.9 (12.9; 19.3) 45/274 16.4 (12.2; 21.4)
Unsolicited AE 20/542 3.7 (2.3; 5.6) 7/274 2.6 (1.0; 5.2)
Unsolicited AR 6/542 1.1 (0.4; 2.4) 1/274 0.4 (0.0; 2.0)
Unsolicited non-serious AE 19/542 3.5 (2.1; 5.4) 7/274 2.6 (1.0; 5.2)
Unsolicited non-serious AR 6/542 1.1 (0.4; 2.4) 1/274 0.4 (0.0; 2.0)
Unsolicited non-serious injection site AR 0/542 0.0 (0.0; 0.7) 0/274 0.0 (0.0; 1.3)
Unsolicited non-serious systemic AE 19/542 3.5 (2.1; 5.4) 7/274 2.6 (1.0; 5.2)
Unsolicited non-serious systemic AR 6/542 1.1 (0.4; 2.4) 1/274 0.4 (0.0; 2.0)
AE  leading to study discontinuationa 8/542 1.5 (0.6; 2.9) 2/274 0.7 (0.1; 2.6)
SAE  collected up to 28 days after last vaccination 2/542 0.4 (0.0; 1.3) 0/274 0.0 (0.0; 1.3)
SAE  collected during 6-month follow-up 0/542 0.0 (0.0; 0.7) 0/274 0.0 (0.0; 1.3)
SAE  collected up to the end of 6-month follow-up 2/542 0.4 (0.0; 1.3) 0/274 0.0 (0.0; 1.3)
Death  0/542 0.0 (0.0; 0.7) 0/274 0.0 (0.0; 1.3)
n: number of subjects experiencing the endpoint.
M:  number of subjects with available data for the relevant endpoint.
AE  = adverse event; AR = adverse reaction.
a Identiﬁed in the termination form as SAE or other AE up to 28 days after the last vaccination.
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nd ARs after each successive injection.
Overall, 10 subjects experienced AEs that led to study discontin-
ation. One subject was withdrawn by the Investigator after Level
I dog bite (unrelated SAE) 3 days after the second dose of PVRV-NG.
his 38-year-old woman received 5 doses of a commercial rabies
accine as PEP. In the younger age range, two subjects, one from
ach group, were discontinued by the Investigator due to Grade
I urticaria after the ﬁrst vaccination. Both cases resolved within
 days after healthcare contact. Additionally, seven subjects (six in
he PVRV-NG group and one in the Verorab group) discontinued the
Solicited systemic rea
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study after they experienced AEs such as urticaria, common cold,
malaise, headache, and pharyngalgia. These were all Grade I events
of short duration that resolved spontaneously.
4. Discussion
PVRV-NG is a next-generation, highly puriﬁed rabies vaccine
developed with innovative technology in human- and animal-
free medium as an evolution of the reference vaccine Verorab.
The vaccine beneﬁts from decades of experience gathered from
the administration of Verorab to millions of people in over 100
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ountries for the pre- and post-exposure prophylaxis of rabies.
oreover, PVRV-NG complies with the European Union pharma-
opeia and the speciﬁcations deﬁned by the WHO  and the US Food
nd Drug Administration (FDA).
As was already shown for pre-exposure in a Phase II trial [5],
his Phase III trial demonstrated the immunogenic non-inferiority
f PVRV-NG compared with Verorab after three doses of a post-
xposure regimen, with regards to RVNA titers in healthy subjects
ged 10 years and over, regardless of gender, pre-vaccination titer
nd age. All subjects reached the 0.5 IU/mL seroconversion thresh-
ld after three doses, apart from one subject in the PVRV-NG
roup and one in the Verorab group who reached the threshold
fter completion of the full schedule. No further information could
e collected to explain why their immune response was delayed,
xcept for the concomitant intake of cephalosporin by one of these
ubjects for the treatment of chronic faucitis. Such delayed immune
esponse is rare and was reported in a recent rabies study in China
8]. The GMTs were similar between the groups and in both the
PAS and the FAS. A marked increase in GMTs after three injec-
ions and a further increase 14 days after completion of the 5-dose
chedule were observed with both vaccines.
PVRV-NG was safe and well tolerated after each injection
nd until 6 months after the last dose. The vaccine had a
imilar safety proﬁle to Verorab with regards to the nature,
requency, duration and severity of AEs and ARs. With around
6% of subjects who reported at least one solicited reaction,
he younger subjects in both groups tended to report more
eactions than the older subjects (around 20%), regardless of
hether they received PVRV-NG or Verorab. No safety signals
merged and reactogenicity did not increase with the successive
njections.
Through this Phase III clinical trial, it was conﬁrmed that the
ext-generation serum-free PVRV-NG vaccine, an evolution over
he reference vaccine Verorab, is both safe and immunogenic, offer-
ng a new alternative for the prophylaxis of rabies.
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